Asset Details
Do you wish to reserve the book?
The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial
Do you wish to request the book?
The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial
2014
Overview
Assess insulin sensitivity after treatment with a selective PPAR-alpha agonist compared to an HMG CoA reductase inhibitor in human subjects with type 2 diabetes mellitus.
Thirteen subjects with Type 2 diabetes mellitus were studied in a double-blind crossover design with 4-week placebo run-in and washout and 12-week treatment periods, randomised to micronised fenofibrate 267mg or atorvastatin 10mg daily followed by the alternate drug in the second period. Insulin resistance was measured using the isoglycaemic hyperinsulinaemic clamp method with isotope dilution.
Weight, physical activity and other medications did not change. Total cholesterol (mean +/− standard error) was 4.60+/−0.21 versus 3.9+/−0.22mmol/L after fenofibrate and atorvastatin respectively, p<0.05. LDL was 2.70+/−0.19 versus 1.95+/−0.23mmol/L, p<0.05 and triglyceride 1.64+/−0.23 versus 1.84+/−0.26mmol/L, p<0.05. Insulin-stimulated whole-body glucose disposal (35.4+/−3.1 versus 33.2+/−3.0μmol/kg/min) and nadir endogenous glucose production (6.2+/−1.4 versus 7.0+/−1.1μmol/kg/min) revealed no significant differences in effects of the treatments.
In human subjects with Type 2 diabetes mellitus there were characteristic differences in lipid profile changes but no difference in insulin sensitivity after treatment with micronised fenofibrate compared to atorvastatin. This study finds no evidence of increased insulin sensitivity using this selective PPAR-alpha agonist over a commonly used statin at these doses.
Publisher
Elsevier Inc,Elsevier Limited
Subject
/ Diabetes
/ Diabetes Mellitus, Type 2 - blood
/ Diabetes Mellitus, Type 2 - physiopathology
/ Dose-Response Relationship, Drug
/ Fibrate
/ Glucose
/ Heptanoic Acids - pharmacology
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
/ Hypolipidemic Agents - pharmacology
/ Insulin
/ Insulin Resistance - physiology
/ Kinases
/ Lipids
/ Male
/ Peroxisome proliferator-activated receptor alpha
/ Statin
/ Studies
